Go Pro
→ Why I went to Mount Rushmore (From Stansberry Research) (Ad)tc pixel Free RVX Stock Alerts

Resverlogix (RVX) Competitors

Resverlogix logo
C$0.09 +0.01 (+5.88%)
As of 09/23/2026 03:49 PM Eastern
Compare

RVX vs. HBP, SCYB, COM, NVH, and COV

Should you buy Resverlogix stock or one of its competitors? Resverlogix's main competitors and comparable companies include Helix BioPharma (HBP), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), and Covalon Technologies (COV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Resverlogix compare to Helix BioPharma?

Resverlogix (TSE:RVX) and Helix BioPharma (TSE:HBP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

Helix BioPharma is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResverlogixN/AN/A-C$2.81M-C$0.04N/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A

In the previous week, Helix BioPharma had 1 more articles in the media than Resverlogix. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for Resverlogix. Resverlogix's average media sentiment score of 0.00 equaled Helix BioPharma'saverage media sentiment score.

Company Overall Sentiment
Resverlogix Neutral
Helix BioPharma Neutral

Resverlogix's return on equity of 10.92% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
ResverlogixN/A 10.92% -34.90%
Helix BioPharma N/A -21.54%-279.98%

0.0% of Resverlogix shares are owned by institutional investors. Comparatively, 0.0% of Helix BioPharma shares are owned by institutional investors. 42.7% of Resverlogix shares are owned by company insiders. Comparatively, 2.2% of Helix BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Resverlogix has a beta of 0.119614, meaning that its stock price is 88% less volatile than the broader market. Comparatively, Helix BioPharma has a beta of 0.722962, meaning that its stock price is 28% less volatile than the broader market.

Summary

Resverlogix beats Helix BioPharma on 6 of the 8 factors compared between the two stocks.

How does Resverlogix compare to Scythian Biosciences?

Resverlogix (TSE:RVX) and Scythian Biosciences (CVE:SCYB) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

In the previous week, Resverlogix's average media sentiment score of 0.00 equaled Scythian Biosciences'average media sentiment score.

Company Overall Sentiment
Resverlogix Neutral
Scythian Biosciences Neutral

Resverlogix's return on equity of 10.92% beat Scythian Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
ResverlogixN/A 10.92% -34.90%
Scythian Biosciences N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResverlogixN/AN/A-C$2.81M-C$0.04N/A
Scythian BiosciencesN/AN/AN/AN/AN/A

0.0% of Resverlogix shares are held by institutional investors. 42.7% of Resverlogix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Resverlogix beats Scythian Biosciences on 3 of the 4 factors compared between the two stocks.

How does Resverlogix compare to 138267 (COM.TO)?

Resverlogix (TSE:RVX) and 138267 (COM.TO) (TSE:COM) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

0.0% of Resverlogix shares are held by institutional investors. 42.7% of Resverlogix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Resverlogix's average media sentiment score of 0.00 equaled 138267 (COM.TO)'saverage media sentiment score.

Company Overall Sentiment
Resverlogix Neutral
138267 (COM.TO) Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResverlogixN/AN/A-C$2.81M-C$0.04N/A
138267 (COM.TO)N/AN/AN/AN/AN/A

Resverlogix's return on equity of 10.92% beat 138267 (COM.TO)'s return on equity.

Company Net Margins Return on Equity Return on Assets
ResverlogixN/A 10.92% -34.90%
138267 (COM.TO) N/A N/A N/A

Summary

Resverlogix beats 138267 (COM.TO) on 3 of the 4 factors compared between the two stocks.

How does Resverlogix compare to Novoheart?

Novoheart (CVE:NVH) and Resverlogix (TSE:RVX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Resverlogix has lower revenue, but higher earnings than Novoheart. Novoheart is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoheartC$423.50K236.08-C$7.17M-C$0.04N/A
ResverlogixN/AN/A-C$2.81M-C$0.04N/A

In the previous week, Novoheart's average media sentiment score of 0.00 equaled Resverlogix'saverage media sentiment score.

Company Overall Sentiment
Novoheart Neutral
Resverlogix Neutral

0.0% of Resverlogix shares are held by institutional investors. 42.7% of Resverlogix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Resverlogix's return on equity of 10.92% beat Novoheart's return on equity.

Company Net Margins Return on Equity Return on Assets
NovoheartN/A N/A N/A
Resverlogix N/A 10.92%-34.90%

Summary

Resverlogix beats Novoheart on 5 of the 8 factors compared between the two stocks.

How does Resverlogix compare to Covalon Technologies?

Covalon Technologies (CVE:COV) and Resverlogix (TSE:RVX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

In the previous week, Covalon Technologies had 1 more articles in the media than Resverlogix. MarketBeat recorded 1 mentions for Covalon Technologies and 0 mentions for Resverlogix. Covalon Technologies' average media sentiment score of 1.18 beat Resverlogix's score of 0.00 indicating that Covalon Technologies is being referred to more favorably in the media.

Company Overall Sentiment
Covalon Technologies Positive
Resverlogix Neutral

Covalon Technologies has higher revenue and earnings than Resverlogix. Resverlogix is trading at a lower price-to-earnings ratio than Covalon Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Covalon TechnologiesC$34.35M3.26C$2.39MC$0.1625.38
ResverlogixN/AN/A-C$2.81M-C$0.04N/A

Covalon Technologies has a beta of 1.397953, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Resverlogix has a beta of 0.119614, meaning that its stock price is 88% less volatile than the broader market.

Covalon Technologies has a net margin of 12.78% compared to Resverlogix's net margin of 0.00%. Covalon Technologies' return on equity of 15.04% beat Resverlogix's return on equity.

Company Net Margins Return on Equity Return on Assets
Covalon Technologies12.78% 15.04% -3.25%
Resverlogix N/A 10.92%-34.90%

0.2% of Covalon Technologies shares are held by institutional investors. Comparatively, 0.0% of Resverlogix shares are held by institutional investors. 48.7% of Covalon Technologies shares are held by insiders. Comparatively, 42.7% of Resverlogix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Covalon Technologies beats Resverlogix on 12 of the 12 factors compared between the two stocks.

Get Resverlogix News Delivered to You Automatically

Sign up to receive the latest news and ratings for RVX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RVX vs. The Competition

Export
MetricResverlogixBiotechnology IndustryHealthcare SectorTSE Exchange
Market CapC$30.99MC$3.98BC$7.31BC$12.84B
Dividend Yield7.02%3.63%2.52%6.27%
P/E Ratio-2.2513.88274.0740.36
Price / SalesN/A1,356.95643.139.35
Price / Cash132.50113.2977.8082.29
Price / Book-0.3115.4010.474.69
Net Income-C$2.81M-C$22.82MC$3.49BC$299.09M
7 Day PerformanceN/A-1.71%-0.67%0.01%
1 Month PerformanceN/A-6.18%-3.17%-2.14%
1 Year PerformanceN/A30.64%15.13%20.17%

Resverlogix Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RVX
Resverlogix
N/AC$0.09
+5.9%		N/A+0.0%C$30.99MN/AN/A19
HBP
Helix BioPharma
N/AC$1.40
-3.4%		N/A-31.3%C$110.75MN/AN/A9
SCYB
Scythian Biosciences
N/AC$3.49
-5.9%		N/A+0.0%C$102.38MN/AN/AN/A
COM
138267 (COM.TO)
N/AN/AN/AN/AC$102.19MN/AN/AN/A
NVH
Novoheart
N/AC$0.53
+1.9%		N/A+0.0%C$99.98MC$423.50KN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:RVX) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Why I believe the AI market will split in Q4
Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...
The Oxford Club | Sponsoredtc pixel
Why I went to Mount Rushmore
A small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...
Stansberry Research | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Barricks gold output fell from 2 million ounces to 719000
Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...
Golden Portfolio | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...
Banyan Hill Publishing | Sponsoredtc pixel